CNTA Stock Overview
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Centessa Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.78 |
| 52 Week High | US$12.45 |
| 52 Week Low | US$3.96 |
| Beta | 1.38 |
| 1 Month Change | 1.51% |
| 3 Month Change | 41.28% |
| 1 Year Change | 123.65% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.44% |
Recent News & Updates
Recent updates
Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?
Mar 07
Centessa Pharmaceuticals snaps multi-day losing streak; up 10%
Oct 20Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status
Sep 14Centessa Pharmaceuticals GAAP EPS of -$0.69
Aug 10Checking In On Centessa Pharmaceuticals
Dec 23Centessa Pharmaceuticals stock pops 20%+ intraday to post-IPO high
Jun 14Shareholder Returns
| CNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.3% | -4.2% | -3.7% |
| 1Y | 123.7% | -2.0% | 20.5% |
Return vs Industry: CNTA exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: CNTA exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| CNTA volatility | |
|---|---|
| CNTA Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CNTA's share price has been volatile over the past 3 months.
Volatility Over Time: CNTA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 76 | Saurabh Saha | www.centessa.com |
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861.
Centessa Pharmaceuticals plc Fundamentals Summary
| CNTA fundamental statistics | |
|---|---|
| Market cap | US$1.11b |
| Earnings (TTM) | -US$151.08m |
| Revenue (TTM) | US$6.85m |
157.8x
P/S Ratio-7.2x
P/E RatioIs CNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNTA income statement (TTM) | |
|---|---|
| Revenue | US$6.85m |
| Cost of Revenue | US$0 |
| Gross Profit | US$6.85m |
| Other Expenses | US$157.94m |
| Earnings | -US$151.08m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.51 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,204.65% |
| Debt/Equity Ratio | 32.0% |
How did CNTA perform over the long term?
See historical performance and comparison